When was Leukocare founded?

Leukocare was founded in 2003 and raised its 1st funding round 12 years after it was founded.

Where is Leukocare located?

Leukocare is headquartered in Germany.

How many employees does Leukocare have?

As of Sep 30, 2026, the latest employee count at Leukocare is 56.

Is Leukocare a funded company?

Leukocare is a funded company, having raised a total of $17.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 22, 2015.

When was the latest funding round of Leukocare?

Leukocare's latest funding was a $***** Series B round on Jun 23, 2021, with participation from 1 investor.

Where does Leukocare rank among its competitors?

Leukocare ranks 7th amongst 898 active competitors, of which 31 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Nivagen Pharmaceuticals, which secured $5M in Aug, 2023.

Who are the top competitors of Leukocare?

Leukocare's top competitors include Nivagen Pharmaceuticals, Jubilant Life Sciences and Windlas. Among them, Nivagen Pharmaceuticals secured the most recent funding round in August, 2023.

Leukocare - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Leukocare offers a proprietary formulation platform for the development of biologics. Their proprietary Stabilising and Protecting Solutions (SPS) platform offers technologies for increasing the stability and protection of therapeutic proteins in dry and liquid formulations. The platform mainly includes three major functionalities namely thermal stabilization, sterilization protection (for terminal sterilization and dry formulation of biologics) and device functionalization (for medical devices). The platform can be used mainly for the development of therapeutic antibodies, biosimilars, vaccines and medical devices. The company recently entered into a strategic alliance with Rentschler Biotechnologie, a Germany-based CDMO through which Leukocare would become its specialized technology partner and exclusive formulation developer.

Website: www.leukocare.com/
Social
Email ID: *****@leukocare.com
Phone Number: +49 **********

Key Metrics

Founded Year

2003

Location

Germany

Stage

Series B

Total Funding

$17.5M in 2 rounds

Latest Funding Round

Series B, Jun 23, 2021, $*****

Investors

Petrichor & 1 more

Ranked

7^th among 898 active competitors

Employee Count

56 as on Sep 30, 2026

Similar Companies

Nivagen Pharmaceuticals & 1108 more

View Leukocare's full profile

Leukocare is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Leukocare Ag CIN: HRB153880 , Germany, Active	Sep 12, 2004	-	70 (As on Dec 31, 2021)

Leukocare has raised a total funding of $17.5M over 2 rounds. Its first funding round was on Jul 22, 2015. Its latest funding round was a Series B round on Jun 23, 2021 for $*****. 1 investor participated in its latest round. Leukocare has 2 institutional investors.

Here is the list of recent funding rounds of Leukocare:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 23, 2021	6656200	Series B	7469092	9212722	2885021	7932200
Jul 22, 2015	1065602	Series A	2803552	2902908	4486158	LifeCare Partners

Access funding benchmarks and valuations. Sign up today!

View details of Leukocare's funding rounds and investors

The founders of Leukocare is Michael Scholl.

Here are the details of Leukocare's key team members:

Michael Scholl: Chief Executive Officer; Co-Founder of Leukocare.

View details of Leukocare's Founder profiles and Board Members

Leukocare's employee count trend

Leukocare has 56 employees as of Sep 26. Here is Leukocare's employee count trend over the years:

Uncover Leukocare's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Leukocare include Nivagen Pharmaceuticals, Jubilant Life Sciences and Windlas. Here is the list of Top 10 competitors of Leukocare, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nivagen Pharmaceuticals 2009, Sacramento (United States), Acquired	Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution	$31M	Telegraph Hill Partners, BizCap & 2 others	60/100
2nd	Jubilant Life Sciences 1978, Noida (India), Public	Company offering a suite of R&D and manufacturing services for small molecules and generics	-	Samena Capital, General Atlantic & 1 others	59/100
3rd	Windlas 2001, Gurugram (India), Public	Provider of regulatory affair, quality control, and market strategy services to biopharma sector	$13M	Tano Capital, HDFC Bank & 6 others	59/100
4th	Asahi Kasei 1931, Chiyoda-ku (Japan), Public	CDMO focused on manufacturing of liquid, solid & injectable drug formulations	-	Europa	55/100
5th	Unither 1993, Paris (France), Acquired	Contract development and manufacturing organization for proprietary and generic drugs	-	Credit Mutuel Equity, Picardie Investissement ... & 11 others	54/100
6th	Labiana 1958, Corbera de Llobregat (Spain), Unfunded	Contract laboratory and contract manufacturing services for pharmaceutical and animal health industries	-	-	54/100
7th	Leukocare 2003, Germany, Series B	Developer of proprietary stabilizing and protecting solutions for biologics formulation	$17.5M	Petrichor, LifeCare Partners	54/100
8th	Chugai Pharmaceutical 1925, Tokyo (Japan), Acquired	Developer of innovative pharmaceutical products and services	-	Digital Pharma Lab	54/100
9th	SAVA group 2003, Pune (India), Unfunded	Pharma company with a portfolio of domestic and export products, also offering CRAMS services	-	-	53/100
10th	MedPharm 1998, Guildford (United Kingdom), Late Stage	Developer and manufacturer of API and pharmaceutical formulations	-	Orbimed, Ampersand Capital	53/100